Bausch + Lomb announced that the FDA has approved the enVista Envy full range of vision intraocular lens, or IOL, which offers a continuous range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- TPG, Blackstone teaming for Bausch + Lomb bid, may be up to $25/share, FT says
- Bausch + Lomb price target raised to $19 from $17 at Evercore ISI
- Bausch + Lomb Unveils New E-Commerce Platform, Opal
- Bausch + Lomb price target raised to $22 from $19 at H.C. Wainwright
- Bausch + Lomb price target raised to $19 from $16 at Stifel